(BMRN) Biomarin Pharmaceutical - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US09061G1013
Stock: Rare Disease Therapies, Enzyme Replacement, Genetic Disorders
Total Rating 34
Risk 76
Buy Signal -1.33
| Risk 5d forecast | |
|---|---|
| Volatility | 32.5% |
| Relative Tail Risk | -11.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.38 |
| Alpha | -25.86 |
| Character TTM | |
|---|---|
| Beta | 0.468 |
| Beta Downside | 1.413 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.69% |
| CAGR/Max DD | -0.29 |
EPS (Earnings per Share)
Revenue
Description: BMRN Biomarin Pharmaceutical March 05, 2026
BioMarin Pharmaceutical Inc. (BMRN) is a biotechnology company focused on developing and commercializing therapies for rare diseases globally. The companys product portfolio includes treatments for conditions like mucopolysaccharidosis (MPS), achondroplasia, and hemophilia A. The biotechnology sector is characterized by high research and development costs and long development cycles.
BMRNs business model involves both enzyme replacement therapies and gene therapies. The company serves a diverse customer base including specialty pharmacies, hospitals, and government agencies. License and collaboration agreements are common in the pharmaceutical industry to share development costs and expand market reach. For more detailed financial analysis, ValueRay can provide further insights.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 348.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.74 > 1.0 |
| NWC/Revenue: 99.17% < 20% (prev 91.99%; Δ 7.17% < -1%) |
| CFO/TA 0.11 > 3% & CFO 828.0m > Net Income 348.9m |
| Net Debt (-714.5m) to EBITDA (572.9m): -1.25 < 3 |
| Current Ratio: 5.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (197.4m) vs 12m ago 0.41% < -2% |
| Gross Margin: 77.13% > 18% (prev 0.80%; Δ 7633 % > 0.5%) |
| Asset Turnover: 44.18% > 50% (prev 40.83%; Δ 3.34% > 0%) |
| Interest Coverage Ratio: 45.27 > 6 (EBITDA TTM 572.9m / Interest Expense TTM 10.9m) |
Altman Z'' 3.37
| A: 0.42 (Total Current Assets 3.95b - Total Current Liabilities 759.0m) / Total Assets 7.59b |
| B: 0.02 (Retained Earnings 154.2m / Total Assets 7.59b) |
| C: 0.07 (EBIT TTM 493.4m / Avg Total Assets 7.29b) |
| D: 0.09 (Book Value of Equity 130.4m / Total Liabilities 1.51b) |
| Altman-Z'' Score: 3.37 = A |
Beneish M -2.84
| DSRI: 1.22 (Receivables 908.2m/660.5m, Revenue 3.22b/2.85b) |
| GMI: 1.03 (GM 77.13% / 79.67%) |
| AQI: 0.91 (AQ_t 0.35 / AQ_t-1 0.39) |
| SGI: 1.13 (Revenue 3.22b / 2.85b) |
| TATA: -0.06 (NI 348.9m - CFO 828.0m) / TA 7.59b) |
| Beneish M-Score: -2.84 (Cap -4..+1) = A |
What is the price of BMRN shares?
As of March 05, 2026, the stock is trading at USD 60.43 with a total of 1,978,843 shares traded.
Over the past week, the price has changed by -6.53%, over one month by +1.60%, over three months by +7.77% and over the past year by -17.59%.
Over the past week, the price has changed by -6.53%, over one month by +1.60%, over three months by +7.77% and over the past year by -17.59%.
Is BMRN a buy, sell or hold?
Biomarin Pharmaceutical has received a consensus analysts rating of 4.34.
Therefore, it is recommended to buy BMRN.
- StrongBuy: 16
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BMRN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88.4 | 46.3% |
| Analysts Target Price | 88.4 | 46.3% |
BMRN Fundamental Data Overview March 04, 2026
P/E Trailing = 22.2082
P/E Forward = 11.7925
P/S = 3.5629
P/B = 1.8949
P/EG = 0.5313
Revenue TTM = 3.22b USD
EBIT TTM = 493.4m USD
EBITDA TTM = 572.9m USD
Long Term Debt = 597.2m USD (from longTermDebt, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, two quarters ago)
Debt = 597.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -714.5m USD (from netDebt column, last quarter)
Enterprise Value = 10.51b USD (11.48b + Debt 597.2m - CCE 1.56b)
Interest Coverage Ratio = 45.27 (Ebit TTM 493.4m / Interest Expense TTM 10.9m)
EV/FCF = 14.50x (Enterprise Value 10.51b / FCF TTM 725.0m)
FCF Yield = 6.90% (FCF TTM 725.0m / Enterprise Value 10.51b)
FCF Margin = 22.51% (FCF TTM 725.0m / Revenue TTM 3.22b)
Net Margin = 10.83% (Net Income TTM 348.9m / Revenue TTM 3.22b)
Gross Margin = 77.13% ((Revenue TTM 3.22b - Cost of Revenue TTM 736.8m) / Revenue TTM)
Gross Margin QoQ = 66.26% (prev 81.95%)
Tobins Q-Ratio = 1.38 (Enterprise Value 10.51b / Total Assets 7.59b)
Interest Expense / Debt = 0.47% (Interest Expense 2.78m / Debt 597.2m)
Taxrate = 27.69% (133.6m / 482.5m)
NOPAT = 356.8m (EBIT 493.4m * (1 - 27.69%))
Current Ratio = 5.21 (Total Current Assets 3.95b / Total Current Liabilities 759.0m)
Debt / Equity = 0.10 (Debt 597.2m / totalStockholderEquity, last quarter 6.09b)
Debt / EBITDA = -1.25 (Net Debt -714.5m / EBITDA 572.9m)
Debt / FCF = -0.99 (Net Debt -714.5m / FCF TTM 725.0m)
Total Stockholder Equity = 5.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 348.9m / Total Assets 7.59b)
RoE = 5.82% (Net Income TTM 348.9m / Total Stockholder Equity 5.99b)
RoCE = 7.49% (EBIT 493.4m / Capital Employed (Equity 5.99b + L.T.Debt 597.2m))
RoIC = 5.42% (NOPAT 356.8m / Invested Capital 6.59b)
WACC = 7.31% (E(11.48b)/V(12.07b) * Re(7.67%) + D(597.2m)/V(12.07b) * Rd(0.47%) * (1-Tc(0.28)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.44%
[DCF] Terminal Value 83.55% ; FCFF base≈625.1m ; Y1≈771.2m ; Y5≈1.31b
[DCF] Fair Price = 138.0 (EV 25.80b - Net Debt -714.5m = Equity 26.51b / Shares 192.1m; r=7.31% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 64.81 | EPS CAGR: 28.43% | SUE: -0.89 | # QB: 0
Revenue Correlation: 97.53 | Revenue CAGR: 14.91% | SUE: 1.48 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.17 | Chg7d=-0.141 | Chg30d=-0.127 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=5.31 | Chg7d=-0.025 | Chg30d=+0.031 | Revisions Net=-3 | Growth EPS=+68.5% | Growth Revenue=+19.0%
EPS next Year (2027-12-31): EPS=6.68 | Chg7d=+1.030 | Chg30d=+1.054 | Revisions Net=+0 | Growth EPS=+25.8% | Growth Revenue=+16.9%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +9.0% (Analyst 12.4% - Implied 3.4%)
P/E Forward = 11.7925
P/S = 3.5629
P/B = 1.8949
P/EG = 0.5313
Revenue TTM = 3.22b USD
EBIT TTM = 493.4m USD
EBITDA TTM = 572.9m USD
Long Term Debt = 597.2m USD (from longTermDebt, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, two quarters ago)
Debt = 597.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -714.5m USD (from netDebt column, last quarter)
Enterprise Value = 10.51b USD (11.48b + Debt 597.2m - CCE 1.56b)
Interest Coverage Ratio = 45.27 (Ebit TTM 493.4m / Interest Expense TTM 10.9m)
EV/FCF = 14.50x (Enterprise Value 10.51b / FCF TTM 725.0m)
FCF Yield = 6.90% (FCF TTM 725.0m / Enterprise Value 10.51b)
FCF Margin = 22.51% (FCF TTM 725.0m / Revenue TTM 3.22b)
Net Margin = 10.83% (Net Income TTM 348.9m / Revenue TTM 3.22b)
Gross Margin = 77.13% ((Revenue TTM 3.22b - Cost of Revenue TTM 736.8m) / Revenue TTM)
Gross Margin QoQ = 66.26% (prev 81.95%)
Tobins Q-Ratio = 1.38 (Enterprise Value 10.51b / Total Assets 7.59b)
Interest Expense / Debt = 0.47% (Interest Expense 2.78m / Debt 597.2m)
Taxrate = 27.69% (133.6m / 482.5m)
NOPAT = 356.8m (EBIT 493.4m * (1 - 27.69%))
Current Ratio = 5.21 (Total Current Assets 3.95b / Total Current Liabilities 759.0m)
Debt / Equity = 0.10 (Debt 597.2m / totalStockholderEquity, last quarter 6.09b)
Debt / EBITDA = -1.25 (Net Debt -714.5m / EBITDA 572.9m)
Debt / FCF = -0.99 (Net Debt -714.5m / FCF TTM 725.0m)
Total Stockholder Equity = 5.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 348.9m / Total Assets 7.59b)
RoE = 5.82% (Net Income TTM 348.9m / Total Stockholder Equity 5.99b)
RoCE = 7.49% (EBIT 493.4m / Capital Employed (Equity 5.99b + L.T.Debt 597.2m))
RoIC = 5.42% (NOPAT 356.8m / Invested Capital 6.59b)
WACC = 7.31% (E(11.48b)/V(12.07b) * Re(7.67%) + D(597.2m)/V(12.07b) * Rd(0.47%) * (1-Tc(0.28)))
Discount Rate = 7.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.44%
[DCF] Terminal Value 83.55% ; FCFF base≈625.1m ; Y1≈771.2m ; Y5≈1.31b
[DCF] Fair Price = 138.0 (EV 25.80b - Net Debt -714.5m = Equity 26.51b / Shares 192.1m; r=7.31% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 64.81 | EPS CAGR: 28.43% | SUE: -0.89 | # QB: 0
Revenue Correlation: 97.53 | Revenue CAGR: 14.91% | SUE: 1.48 | # QB: 1
EPS next Quarter (2026-06-30): EPS=1.17 | Chg7d=-0.141 | Chg30d=-0.127 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=5.31 | Chg7d=-0.025 | Chg30d=+0.031 | Revisions Net=-3 | Growth EPS=+68.5% | Growth Revenue=+19.0%
EPS next Year (2027-12-31): EPS=6.68 | Chg7d=+1.030 | Chg30d=+1.054 | Revisions Net=+0 | Growth EPS=+25.8% | Growth Revenue=+16.9%
[Analyst] Revisions Ratio: -0.11 (4 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +9.0% (Analyst 12.4% - Implied 3.4%)